Modulation of p53 C-Terminal Acetylation by mdm2, p14ARF, and Cytoplasmic SirT2
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Acetylation of C-terminal lysine residues in the p53 tumor suppressor is associated with increased stability and transcription factor activity. The function, protein level, and acetylation of p53 are downregulated by mdm2, which in its turn is inhibited by the p14ARF tumor suppressor. Here, we show that p14ARF increases the level of p53 acetylated at lysine 382 in a nuclear chromatin-rich fraction. Unexpectedly, this accumulation of p53AcK382 is dramatically enhanced in the presence of ectopic mdm2. In light of these observations, we propose that p14ARF increases the binding of p53–mdm2 complexes to chromatin, thereby limiting the access of protein deacetylases to p53. Supporting this notion, we show that p53AcK382 can be deacetylated in the cytoplasm and that sirtuin SirT2 catalyzes this reaction. These results help understand why inhibition of both SirT1 and SirT2 is needed to achieve effective activation of p53 by small-molecule sirtuin inhibitors. Mol Cancer Ther; 12(4); 471–80. ©2013 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951
Kruse, J.-P., & Gu, W. (2009) · Cell · doi:10.1016/j.cell.2009.04.050 · Cited by 1,610 · cited 1×
“p53 is subjected to a variety of posttranslational modifications that modulate its function as a tumor suppressor (1).”
BackgroundPhylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins
Frye, R. A. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3000 · Cited by 1,409
Nucleolar Arf sequesters Mdm2 and activates p53
Weber, J. D., Taylor, L. J., Roussel, M. F., Sherr, C. J., & Bar-Sagi, D. (1999) · Nature Cell Biology · doi:10.1038/8991 · Cited by 940
Awakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881 · cited 1×
“p53 and therefore is regarded as an attractive target for cancer therapy (12).”
BackgroundMono- Versus Polyubiquitination: Differential Control of p53 Fate by Mdm2
Li, M., Brooks, C. L., Wu-Baer, F., Chen, D., Baer, R., & Gu, W. (2003) · Science · doi:10.1126/science.1091362 · Cited by 804 · cited 1×
“polyubiquitinated and subsequently degraded by the proteasome (37).”
Backgroundp53 Opens the Mitochondrial Permeability Transition Pore to Trigger Necrosis
Vaseva, A. V., Marchenko, N. D., Ji, K., Tsirka, S. E., Holzmann, S., & Moll, U. M. (2012) · Cell · doi:10.1016/j.cell.2012.05.014 · Cited by 740
MDM2–HDAC1-mediated deacetylation of p53 is required for its degradation
Ito, A., Kawaguchi, Y., Lai, C., Kovacs, J. J., Higashimoto, Y., Appella, E., & Yao, T. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf616 · Cited by 570 · cited 4×
“For instance, it has been shown thatmdm2 inhibits p300-mediated p53 acetylation by forming a ternary complex with these 2 proteins (15) and that mdm2–HDAC1 complexes enhance p53 deacetylation (18).”
BackgroundInfluentialShaulsky, G., Goldfinger, N., Ben-Ze'ev, A., & Rotter, V (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.12.6565 · Cited by 356
Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53
Tao, W., & Levine, A. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.3077 · Cited by 355
Cited by
Regulation of the p53 response and its relationship to cancer
Meek, D. W. (2015) · Biochemical Journal · doi:10.1042/bj20150517 · Cited by 288
Stein, L. R., & Imai, S. (2014) · The EMBO Journal · doi:10.1002/embj.201386917 · Cited by 265
“As Sirt1 and Sirt2 can deacetylate p53 (Polager & Ginsberg, 2009; van Leeuwen et al, 2013), it will be interesting to investigate the NAD+ dependence of Olig2 activity.”
BackgroundChen, J., Sysol, J. R., Singla, S., Zhao, S., Yamamura, A., Valdez-Jasso, D., Abbasi, T., Shioura, K. M., Sahni, S., Reddy, V., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.024557 · Cited by 86
Sun, S., Han, X., Li, X., Song, Q., Lu, M., Jia, M., Ding, J., & Hu, G. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00381 · Cited by 77
Metadata
- Authors
- van Leeuwen, I. M. M., Higgins, M., Campbell, J., McCarthy, A. R., Sachweh, M. C. C., Navarro, A. M., & Laín, S.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2013-04-01
- Volume
- 12
- Issue
- 4
- Pages
- 471-480
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2129647444
- Cited by
- 46
- References
- 14
- FWCI
- 2.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Modulation of p53 C-Terminal Acetylation by mdm2, p14ARF, and Cytoplasmic SirT2. https://app.cochat.ai/papers/10.1158/1535-7163.mct-12-0904
- The paper
- van Leeuwen, I. M. M., Higgins, M., Campbell, J., McCarthy, A. R., Sachweh, M. C. C., Navarro, A. M., & Laín, S. (2013). Modulation of p53 C-Terminal Acetylation by mdm2, p14ARF, and Cytoplasmic SirT2. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-12-0904
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.